Tadalafil Mylan

Country: Европска Унија

Језик: Енглески

Извор: EMA (European Medicines Agency)

Купи Сада

Активни састојак:

tadalafil

Доступно од:

Mylan Pharmaceuticals Limited

АТЦ код:

G04BE08

INN (Међународно име):

tadalafil

Терапеутска група:

Urologicals

Терапеутска област:

Erectile Dysfunction

Терапеутске индикације:

Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Mylan is not indicated for use by women.

Резиме производа:

Revision: 15

Статус ауторизације:

Authorised

Датум одобрења:

2014-11-21

Информативни летак

                                61
B. PACKAGE LEAFLET
62
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TADALAFIL MYLAN 2.5 MG FILM-COATED TABLETS
tadalafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Tadalafil Mylan is and what it is used for
2.
What you need to know before you take Tadalafil Mylan
3.
How to take Tadalafil Mylan
4.
Possible side effects
5.
How to store Tadalafil Mylan
6.
Contents of the pack and other information
1.
WHAT TADALAFIL MYLAN IS AND WHAT IT IS USED FOR
Tadalafil Mylan is a treatment for adult men with erectile
dysfunction. This is when a man cannot get, or
keep a hard, erect penis suitable for sexual activity. Tadalafil has
been shown to significantly improve the
ability of obtaining a hard erect penis suitable for sexual activity.
Tadalafil Mylan contains the active substance tadalafil which belongs
to a group of medicines called
phosphodiesterase type 5 inhibitors. Following sexual stimulation
Tadalafil Mylan works by helping the
blood vessels in your penis to relax, allowing the flow of blood into
your penis. The result of this is
improved erectile function. Tadalafil Mylan will not help you if you
do not have erectile dysfunction.
It is important to note that tadalafil does not work if there is no
sexual stimulation. You and your partner will
need to engage in foreplay, just as you would if you were not taking a
medicine for erectile dysfunction.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TADALAFIL MYLAN
DO NOT TAKE TADALAFIL MYLAN
-
if you are allergic to tadalafil or any of the other ingredie
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tadalafil Mylan 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 2.5 mg tadalafil.
_Excipient with known effect:_
Each film-coated tablet contains 29.74 mg of lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
A light yellow, film-coated, round, biconvex tablet (5.1 ± 0.3 mm)
debossed with ‘M’ on one side of the
tablet and ‘TL over 1’ on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of erectile dysfunction in adult males.
In order for tadalafil to be effective, sexual stimulation is
required.
Tadalafil Mylan is not indicated for use by women.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adult men_
In general, the recommended dose is 10 mg taken prior to anticipated
sexual activity and with or without
food.
In those patients in whom tadalafil 10 mg does not produce an adequate
effect, 20 mg might be tried.
It may be taken at least 30 minutes prior to sexual activity.
The maximum dose frequency is once per day.
Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual
activity and it is not recommended for
continuous daily use.
In patients who anticipate a frequent use of tadalafil (i.e., at least
twice weekly) a once daily regimen with
the lowest doses of tadalafil might be considered suitable, based on
patient choice and the physician’s
judgement.
In these patients the recommended dose is 5 mg taken once a day at
approximately the same time of day. The
dose may be decreased to 2.5 mg once a day based on individual
tolerability.
The appropriateness of continued use of the daily regimen should be
reassessed periodically.
3
Special populations
_Elderly men_
Dose adjustments are not required in elderly patients.
_Men with renal impairment_
Dose adjustments are not required in patients with mild to moderate
renal impairment. For patients with
severe renal impairment 10 mg is t
                                
                                Прочитајте комплетан документ
                                
                            

Документи на другим језицима

Информативни летак Информативни летак Бугарски 30-06-2022
Информативни летак Информативни летак Шпански 30-06-2022
Информативни летак Информативни летак Чешки 30-06-2022
Информативни летак Информативни летак Дански 30-06-2022
Информативни летак Информативни летак Немачки 30-06-2022
Информативни летак Информативни летак Естонски 30-06-2022
Информативни летак Информативни летак Грчки 30-06-2022
Информативни летак Информативни летак Француски 30-06-2022
Карактеристике производа Карактеристике производа Француски 30-06-2022
Информативни летак Информативни летак Италијански 30-06-2022
Карактеристике производа Карактеристике производа Италијански 30-06-2022
Извештај о процени јавности Извештај о процени јавности Италијански 19-12-2014
Информативни летак Информативни летак Летонски 30-06-2022
Информативни летак Информативни летак Литвански 30-06-2022
Карактеристике производа Карактеристике производа Литвански 30-06-2022
Информативни летак Информативни летак Мађарски 30-06-2022
Информативни летак Информативни летак Мелтешки 30-06-2022
Информативни летак Информативни летак Холандски 30-06-2022
Карактеристике производа Карактеристике производа Холандски 30-06-2022
Информативни летак Информативни летак Пољски 30-06-2022
Информативни летак Информативни летак Португалски 30-06-2022
Карактеристике производа Карактеристике производа Португалски 30-06-2022
Извештај о процени јавности Извештај о процени јавности Португалски 19-12-2014
Информативни летак Информативни летак Румунски 30-06-2022
Информативни летак Информативни летак Словачки 30-06-2022
Информативни летак Информативни летак Словеначки 30-06-2022
Карактеристике производа Карактеристике производа Словеначки 30-06-2022
Извештај о процени јавности Извештај о процени јавности Словеначки 19-12-2014
Информативни летак Информативни летак Фински 30-06-2022
Информативни летак Информативни летак Шведски 30-06-2022
Информативни летак Информативни летак Норвешки 30-06-2022
Информативни летак Информативни летак Исландски 30-06-2022
Карактеристике производа Карактеристике производа Исландски 30-06-2022
Информативни летак Информативни летак Хрватски 30-06-2022

Обавештења о претрази у вези са овим производом

Погледајте историју докумената